Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report

Metastatic castration resistant prostate cancer (mCRPC), the advanced stage of prostate cancer (PCa), develops resistance to first line androgen deprivation therapy (ADT). Aberrant androgen receptor (AR) and PI3K-Akt-mTOR signaling pathway are responsible for the development and progression of mCRPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhe, Wei, Wei, Liu, Hongruo, Pan, Evenki, Yang, Peng, Jiang, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669273/
https://www.ncbi.nlm.nih.gov/pubmed/34916807
http://dx.doi.org/10.2147/OTT.S334205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669273/
https://www.ncbi.nlm.nih.gov/pubmed/34916807
http://dx.doi.org/10.2147/OTT.S334205

Ejemplares similares